An expert discusses how medical professionals counsel patients on adverse event (AE) risks with tyrosine kinase inhibitors (TKIs) such as lenvatinib/everolimus by highlighting key safety distinctions, ...

Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib ...

RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared ...

Phase III DIPPER trial shows that adjuvant camrelizumab administered after induction-concurrent chemoradiotherapy ...

In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...

GeekWire Award finalists for Health Innovation of the Year are dominated by ventures that aim to outwit cancer with ...

The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncology Servier will ...

AbbVie’s Elahere (mirvetuximab soravtansine-gynx) has demonstrated consistent survival benefits in a subset of ovarian cancer ...

RBC Capital keeps an Outperform rating and $161 price target on Sarepta (SRPT), noting that while the news of an Elevidys patient death is ...

Cancer isn’t just one disease, but many — each with its own challenges, characteristics, risks and treatments. As we have worked tirelessly to understand this group of diseases, I’ve witnessed a ...

The American College of Physicians strongly recommends adding a triptan to an NSAID to treat adults with moderate to severe ...

Canopy is launching a multiyear partnership with Texas Oncology, one of the country’s largest community-based cancer care ...